Skip to content
Screener

BridgeBio Pharma BBIO Q2 2026 earnings

Reported August 10, 2026 · After market close

Revenue$243.7MBeat by $22.8M
EPS-$0.78Miss by $0.20
Revenue estimate$220.9M
EPS estimate-$0.58
“I'm excited by the growing body of evidence continuing to demonstrate Attruby is the drug of choice for all ATTR-CM patients, and particularly for those who are treatment-naïve, including the first-ever demonstration of early, sustained kidney-protective effects in ATTR-CM alongside the cardiac benefit we've established. Furthermore, this was the quarter all three of our pipeline programs, BBP-418, encaleret, and infigratinib, moved from data into active regulatory review, with our first PDUFA date now set for November 27, 2026, which is a level of strategic execution and discipline I'm proud of. Finally, with the $1 billion preferred equity financing we completed, we have a balance sheet sized to run all three launches at full strength, without diverting resources from the development engine that produced them”
Neil Kumar

Next report

Oct 28, 2026 (in 2 months)
Revenue estimate$267.3M
EPS estimate-$0.67

Financials

Q2 2026

Income statement

See full
Revenue$243.7M+120%
Gross profit$228.6M+114%
Operating income-$107.1M+20.3%
Net income-$155.9M+15.2%
EPS (diluted)-$0.78+17.9%

Balance sheet

See full
Cash & equivalents$680.0M-9.5%
Total debt$3.3B+36,912%
Total equity-$2.5B-40.7%
Total assets$1.2B+12.7%

Cash flow

See full
Operating cash flow-$71.1M+11.9%
CapEx$443.0K-25.4%
Free cash flow-$71.5M+12.0%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$15.52B+63.7%
Enterprise value$18.1B+107%
P/S21.8×-18.4×

Profitability

See full
Gross margin94.4%-1.8pp
Operating margin-69.8%-29.9pp
Net margin-98.5%-40.7pp
FCF margin-61.1%-26.8pp

Returns & leverage

See full
Current ratio1.2×-4.0×

Segments

By product

See full
Cost of license, services, and royalty revenue$17.6M—
Royalty revenue$15.4M—
License and services revenue$5.8M—

By segment

See full
Reportable Segment$243.7M—

FAQ

When did BridgeBio Pharma report Q2 2026 earnings?
BridgeBio Pharma (BBIO) reported Q2 2026 earnings on August 10, 2026 after market close.
What were BridgeBio Pharma's Q2 2026 revenue and EPS?
BridgeBio Pharma reported revenue of $243.7M and eps of $-0.78 for Q2 2026.
Did BridgeBio Pharma beat estimates in Q2 2026?
Revenue beat the consensus estimate of $220.9M by $22.8M. EPS missed the consensus estimate of $-0.58 by $0.20.
How did BridgeBio Pharma's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 120.4% from $110.6M a year earlier and eps grew 17.9% from $-0.95.
Where can I find BridgeBio Pharma's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001743881-26-000026) and the 10-Q periodic report (0001743881-26-000027) directly on SEC EDGAR. The filing index links above go to sec.gov.